GlassScriptPhysician profile
Loretta S Loftus
NPI 1891714895
$8,906.41
in general payments reported to CMS, 2019-2025
14 companies · $4,516 in 2025
The $4,516 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $294 · 2021: $533 · 2022: $774 · 2023: $693 · 2024: $882 · 2025: $4,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,100 · Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,100.00 |
| Food and Beverage | $1,991.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $4,625.51 | 2020-2025 | Enhertu |
| Pfizer INC. | $685.15 | 2019-2023 | |
| Lilly USA, LLC | $646.73 | 2022-2025 | Verzenio |
| Astrazeneca Pharmaceuticals LP | $603.03 | 2019-2025 | Enhertu, Imjudo |
| Athenex Pharmaceutical Division, LLC | $544.05 | 2019 | |
| Glaxosmithkline, LLC. | $502.73 | 2019-2022 | |
| Gilead Sciences, INC. | $269.30 | 2021-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $236.14 | 2023-2025 | |
| Genzyme Corporation | $214.55 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $193.95 | 2019-2024 | |
| Novo Nordisk INC | $121.88 | 2019 | |
| Rigel Pharmaceuticals, INC. | $114.06 | 2024 | Rezlidhia, Tavalisse |
| Eli Lilly and Company | $108.11 | 2021 | |
| Stemline Therapeutics INC. | $41.22 | 2024 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loretta Loftus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.